Latest Articles

Publication Date
All News Scientific
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay

FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay

Published: June 21, 2024, 7 a.m.
Read Full Article
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers

Published: June 20, 2024, 7 a.m.
Read Full Article
Ankura Hospital, Bhubaneswar Launches A State-Of-The-Art Facility Specializing In Advanced Gynaecological Care For Endometriosis And Complex Laparoscopic Surgeries - Odisha Diary

Ankura Hospital, Bhubaneswar Launches A State-Of-The-Art Facility Specializing In Advanced Gynaecological Care For Endometriosis And Complex Laparoscopic Surgeries Odisha Diary

Published: June 20, 2024, 7 a.m.
Read Full Article
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma - AJMC.com Managed Markets Network

FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma AJMC.com Managed Markets Network

Published: June 17, 2024, 7 a.m.
Read Full Article
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer - Oncology News Central

FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer Oncology News Central

Published: June 17, 2024, 7 a.m.
Read Full Article
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive

FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive

Published: June 17, 2024, 7 a.m.
Read Full Article
Abemaciclib Plus Fulvestrant Demonstrates Activity in Advanced Endometrial Cancer - Cancer Therapy Advisor

Abemaciclib Plus Fulvestrant Demonstrates Activity in Advanced Endometrial Cancer Cancer Therapy Advisor

Published: June 11, 2024, 7 a.m.
Read Full Article
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates - PR Newswire

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire

Published: June 1, 2024, 7 a.m.
Read Full Article
Endometriosis CARE Act Reintroduced at the Capitol, EndoFound Is There to Support the Cause - Endometriosis Foundation of America - The Blossom

Endometriosis CARE Act Reintroduced at the Capitol, EndoFound Is There to Support the Cause Endometriosis Foundation of America - The Blossom

Published: May 23, 2024, 7 a.m.
Read Full Article
EndoFound to Be Present in Washington, D.C., on Thursday as Endometriosis CARE Act Is Reintroduced - Endometriosis Foundation of America - The Blossom

EndoFound to Be Present in Washington, D.C., on Thursday as Endometriosis CARE Act Is Reintroduced Endometriosis Foundation of America - The Blossom

Published: May 22, 2024, 7 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!